Latest Corporate News
PHARMASCIENCE CANADA LAUNCHES PMS- ABACAVIR-LAMIVUDINE IN THE TREATMENT OF HIV
With Pharmascience Canada’s launch of Prpms-ABACAVIR-LAMIVUDINE, a generic bioequivalent to PrKIVEXA®, patients living with Human Immunodeficiency Virus (HIV) infection have even more treatment options available to them.
Prpms-ABACAVIR-LAMIVUDINE is available in pill form in 600 mg / 300 mg strengths, and is indicated in antiretroviral combination therapy in the treatment of HIV infection, and in children weighing 25 kg or more, in combination with other antiretroviral agents.
Sobering statistics about HIV:
- Just over one in five people living with HIV in Canada are unaware that they have HIV
- Over 26,000 people living with HIV have died since the beginning of the epidemic
- A person is infected with HIV in Canada every three hours
Regular testing, early detection and new treatment options can offer renewed hope to patients living with HIV. For more information, consult your doctor about the treatment options available.
Congratulations to everyone involved in this launch! Check out our social media posts related to this launch!
PrKIVEXA® is a registered trademark of the ViiV Healthcare group of companies.
 Prpms-ABACAVIR-LAMIVUDINE product monograph
 a. b. c. d. e. f. g. h. Public Health Agency of Canada. Summary: Estimates of HIV Incidence, Prevalence and Proportion Undiagnosed in Canada, 2014. Surveillance and Epidemiology Division, Professional Guidelines and Public Health Practice Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2015. Available at:http://www.catie.ca/sites/default/files/2014-HIV-Estimates-in-Canada-EN.pdf
Back to News